APA (7th ed.) Citation

Patel, A., Shertel, T., Wynd, M., Wadhera, V., Serur, D., Schleich, B., . . . Goldstein, M. (2022). Outcomes of de novo belatacept‐based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization. Nephrology, 27(11), 901. https://doi.org/10.1111/nep.14106

Chicago Style (17th ed.) Citation

Patel, Ankita, Tara Shertel, Michael Wynd, Vikram Wadhera, David Serur, Benjamin Schleich, Yuriy Yushkov, and Michael Goldstein. "Outcomes of De Novo Belatacept‐based Immunosuppression Regimen and Avoidance of Calcineurin Inhibitors in Recipients of Kidney Allografts at Higher Risk for Underutilization." Nephrology 27, no. 11 (2022): 901. https://doi.org/10.1111/nep.14106.

MLA (9th ed.) Citation

Patel, Ankita, et al. "Outcomes of De Novo Belatacept‐based Immunosuppression Regimen and Avoidance of Calcineurin Inhibitors in Recipients of Kidney Allografts at Higher Risk for Underutilization." Nephrology, vol. 27, no. 11, 2022, p. 901, https://doi.org/10.1111/nep.14106.